RxDoctor Payments Data

Lycia Aguiar

Family · Texas City, TXNPI 1154816197

Payments from drug & device makers

$2,564in general payments, 2019–2025

Across 142 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$984
  • Abbott$590
  • Adamas Pharmaceuticals, Inc.$172
  • Neurocrine Biosciences, Inc.$142
  • Teva Pharmaceuticals USA, Inc.$109
  • Amgen$64
  • plus $504 from 16 others

What the payments were for

  • Food & beverage$2,564100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,564 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$25,505
Medicare patients
172
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate24$42,408
UbrelvyUbrogepant19$17,981
BriviactBrivaracetam11$14,885
Aimovig AutoinjectorErenumab-Aooe13$14,092
Rivastigmine30$3,888
Memantine Hcl132$2,380
RivastigmineRivastigmine Tartrate46$2,257
Levetiracetam64$1,971
Gabapentin104$1,464
Propranolol Hcl ErPropranolol Hcl15$932
Mirtazapine21$453
Donepezil Hcl42$429
Duloxetine Hcl23$231
Amitriptyline Hcl28$230
Diazepam11$191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$40$42,40824 claims
AbbVieUbrelvy$984$17,98119 claims
Upsher-smith Laboratories LLCTopiramate$15$17719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.

Other family in Texas City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →